These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 7488319)

  • 1. Effect of isocarbacyclin methyl ester incorporated into lipid microspheres on cutaneous blood flow in rat.
    Sawada K; Taneda K; Katsuura Y; Tanabe H; Kiyoki M; Araki H
    Arzneimittelforschung; 1995 Sep; 45(9):988-90. PubMed ID: 7488319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex vivo anti-platelet effects of isocarbacyclin methyl ester incorporated in lipid microspheres in rabbits.
    Inoue K; Aoki Y; Hayashi M; Kitahara S; Tanabe H; Kiyoki M; Araki H
    Arzneimittelforschung; 1995 Sep; 45(9):980-4. PubMed ID: 7488317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of isocarbacyclin methyl ester incorporated in lipid microspheres on experimental models of peripheral obstructive disease.
    Murakami T; Sawada K; Taneda K; Hayashi M; Katsuura Y; Tanabe H; Kiyoki M; Araki H
    Arzneimittelforschung; 1995 Sep; 45(9):991-4. PubMed ID: 7488320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasorelaxant effect of isocarbacyclin methyl ester incorporated into lipid microspheres on isolated canine arteries.
    Sawada K; Aoki K; Katsuura Y; Tanabe H; Kiyoki M; Araki H
    Arzneimittelforschung; 1995 Sep; 45(9):985-8. PubMed ID: 7488318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-platelet effects of isocarbacyclin methyl ester on human and rabbit platelets in vitro.
    Inoue K; Aoki Y; Kitahara S; Kiyoki M; Araki H
    Arzneimittelforschung; 1995 Sep; 45(9):975-9. PubMed ID: 7488316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exhibition of anti-platelet effect of isocarbacyclin methyl ester and its free acid via an increase in cAMP in platelets.
    Aoki Y; Inoue K; Kitahara S; Kiyoki M; Araki H
    Arzneimittelforschung; 1995 Sep; 45(9):970-4. PubMed ID: 7488315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological properties of the new stable prostacyclin analogue 3-Oxa-methano-prostaglandin I.
    Yamamoto T; Satoh K; Nishimura T; Horikawa N; Mine T; Hirohashi T; Hara Y
    Arzneimittelforschung; 1994 Apr; 44(4):483-90. PubMed ID: 8011001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the isocarbacyclin methyl ester clinprost incorporated into lipid microspheres, in focal ischemia of stroke-prone spontaneously hypertensive rats.
    Yae T; Araki H; O-ogami Y; Iwasaki K; Tanabe H; Fujiwara M
    Arzneimittelforschung; 1997 Nov; 47(11):1200-3. PubMed ID: 9428973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of beraprost sodium on peripheral circulatory disturbances induced by various stimuli.
    Nishio S; Yamada N; Endoh T; Isogaya M; Fukatsu Y; Nishimura S; Kanai N; Umetsu T
    Arzneimittelforschung; 1989 Oct; 39(10):1229-34. PubMed ID: 2514691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulation of prostanoid IP and EP(2) receptors dilates retinal arterioles and increases retinal and choroidal blood flow in rats.
    Mori A; Saito M; Sakamoto K; Narita M; Nakahara T; Ishii K
    Eur J Pharmacol; 2007 Sep; 570(1-3):135-41. PubMed ID: 17628525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective effect of TTC-909, an isocarbacyclin methyl ester incorporated in lipid microspheres, on hippocampal delayed neuronal death of stroke-prone spontaneously hypertensive rats.
    Yamashita K; Kataoka Y; Nakashima MN; Yamashita YS; Tanabe H; Araki H; Niwa M; Taniyama K
    Jpn J Pharmacol; 1996 Aug; 71(4):351-5. PubMed ID: 8886935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cicaprost, an orally active prostacyclin analogue: its effects on platelet aggregation and skin blood flow in normal volunteers.
    Belch JJ; McLaren M; Lau CS; Mackay IR; Bancroft A; McEwen J; Thompson JM
    Br J Clin Pharmacol; 1993 Jun; 35(6):643-7. PubMed ID: 8329292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostaglandin E1 incorporated in lipid microspheres (lipo PGE1).
    Otomo S; Mizushima Y; Aihara H; Yokoyama K; Watanabe M; Yanagawa A
    Drugs Exp Clin Res; 1985; 11(9):627-31. PubMed ID: 3880049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of YM-254890, a specific Galphaq/11 inhibitor, on experimental peripheral arterial disease in rats.
    Uemura T; Takamatsu H; Kawasaki T; Taniguchi M; Yamamoto E; Tomura Y; Uchida W; Miyata K
    Eur J Pharmacol; 2006 Apr; 536(1-2):154-61. PubMed ID: 16566917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effect of OP-41483.alpha-CD, a prostacyclin analog, on peripheral vascular lesion models in rats.
    Wakitani K; Takakuwa T; Sugioka M; Fujitani B; Aishita H
    Jpn J Pharmacol; 1992 May; 59(1):57-63. PubMed ID: 1507658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of beraprost sodium and prostaglandin E1 on skin blood flow in diabetic rats and normal dogs.
    Ueno Y; Yamada N; Koike H; Nishio S
    Gen Pharmacol; 1996 Mar; 27(2):333-5. PubMed ID: 8919652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of BW245C, a prostaglandin dp receptor agonist, on systemic and regional haemodynamics in the anaesthetized rat.
    Koch KA; Wessale JL; Moreland R; Reinhart GA; Cox BF
    Clin Exp Pharmacol Physiol; 2005 Nov; 32(11):931-5. PubMed ID: 16405449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marked enhancement in antithrombotic activity of isocarbacyclin following its incorporation into lipid microspheres.
    Mizushima Y; Igarashi R; Hoshi K; Sim AK; Cleland ME; Hayashi H; Goto J
    Prostaglandins; 1987 Feb; 33(2):161-8. PubMed ID: 3296005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific augmentation of plantar skin blood flow by lipo-PGE1 assessed in tetrodotoxin- and N(G)-nitro-L-arginine-treated rats.
    Chino D; Akimaru S; Kataha K; Ishii K; Nakayama K
    J Cardiovasc Pharmacol; 2000 Apr; 35(4):630-7. PubMed ID: 10774795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
    Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
    Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.